Dogs are man's best friend: In sickness and in health

R. Timothy Bentley, Atique U. Ahmed, Amy B. Yanke, Aaron Cohen-Gadol, Mahua Dey

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

With the median survival of 14.6 months following best available standard of care, malignant gliomas (MGs) remain one of the biggest therapeutic challenges of the modern time. Although the last several decades have witnessed tremendous advancement in our understanding of MG and evolution of many successful preclinical therapeutic strategies, even the most successful preclinical therapeutic strategies often fail to cross the phase I/II clinical trial threshold. One of the significant, but less commonly discussed, barriers in developing effective glioma therapy is the lack of a robust preclinical model. For the last 30 years, rodent orthotopic xenograft models have been extensively used in the preclinical setting. Although they provide a good basic model for understanding tumor biology, their value in successfully translating preclinical therapeutic triumph into clinical success is extremely poor. Companion dogs, which share the same environmental stress as their human counterparts, also spontaneously develop MGs. Dog gliomas that develop spontaneously in an immunocompetent host are very similar to human gliomas and potentially provide a stronger platform for validating the efficacy of therapeutic strategies proven successful in preclinical mouse models. Integrating this model can accelerate development of effective therapeutic options that will benefit both human subjects and pet dogs.

Original languageEnglish (US)
Pages (from-to)312-322
Number of pages11
JournalNeuro-Oncology
Volume19
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Glioma
Dogs
Health
Therapeutics
Phase II Clinical Trials
Clinical Trials, Phase I
Pets
Standard of Care
Heterografts
Rodentia
Survival
Neoplasms

Keywords

  • Canine glioma
  • Comparative oncology
  • Glioblastoma
  • Malignant glioma spontaneous glioma

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Bentley, R. T., Ahmed, A. U., Yanke, A. B., Cohen-Gadol, A., & Dey, M. (2017). Dogs are man's best friend: In sickness and in health. Neuro-Oncology, 19(3), 312-322. https://doi.org/10.1093/neuonc/now109

Dogs are man's best friend : In sickness and in health. / Bentley, R. Timothy; Ahmed, Atique U.; Yanke, Amy B.; Cohen-Gadol, Aaron; Dey, Mahua.

In: Neuro-Oncology, Vol. 19, No. 3, 01.03.2017, p. 312-322.

Research output: Contribution to journalArticle

Bentley, RT, Ahmed, AU, Yanke, AB, Cohen-Gadol, A & Dey, M 2017, 'Dogs are man's best friend: In sickness and in health', Neuro-Oncology, vol. 19, no. 3, pp. 312-322. https://doi.org/10.1093/neuonc/now109
Bentley, R. Timothy ; Ahmed, Atique U. ; Yanke, Amy B. ; Cohen-Gadol, Aaron ; Dey, Mahua. / Dogs are man's best friend : In sickness and in health. In: Neuro-Oncology. 2017 ; Vol. 19, No. 3. pp. 312-322.
@article{1df3ae9cf141410f80ecc6d329dfcc4a,
title = "Dogs are man's best friend: In sickness and in health",
abstract = "With the median survival of 14.6 months following best available standard of care, malignant gliomas (MGs) remain one of the biggest therapeutic challenges of the modern time. Although the last several decades have witnessed tremendous advancement in our understanding of MG and evolution of many successful preclinical therapeutic strategies, even the most successful preclinical therapeutic strategies often fail to cross the phase I/II clinical trial threshold. One of the significant, but less commonly discussed, barriers in developing effective glioma therapy is the lack of a robust preclinical model. For the last 30 years, rodent orthotopic xenograft models have been extensively used in the preclinical setting. Although they provide a good basic model for understanding tumor biology, their value in successfully translating preclinical therapeutic triumph into clinical success is extremely poor. Companion dogs, which share the same environmental stress as their human counterparts, also spontaneously develop MGs. Dog gliomas that develop spontaneously in an immunocompetent host are very similar to human gliomas and potentially provide a stronger platform for validating the efficacy of therapeutic strategies proven successful in preclinical mouse models. Integrating this model can accelerate development of effective therapeutic options that will benefit both human subjects and pet dogs.",
keywords = "Canine glioma, Comparative oncology, Glioblastoma, Malignant glioma spontaneous glioma",
author = "Bentley, {R. Timothy} and Ahmed, {Atique U.} and Yanke, {Amy B.} and Aaron Cohen-Gadol and Mahua Dey",
year = "2017",
month = "3",
day = "1",
doi = "10.1093/neuonc/now109",
language = "English (US)",
volume = "19",
pages = "312--322",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Dogs are man's best friend

T2 - In sickness and in health

AU - Bentley, R. Timothy

AU - Ahmed, Atique U.

AU - Yanke, Amy B.

AU - Cohen-Gadol, Aaron

AU - Dey, Mahua

PY - 2017/3/1

Y1 - 2017/3/1

N2 - With the median survival of 14.6 months following best available standard of care, malignant gliomas (MGs) remain one of the biggest therapeutic challenges of the modern time. Although the last several decades have witnessed tremendous advancement in our understanding of MG and evolution of many successful preclinical therapeutic strategies, even the most successful preclinical therapeutic strategies often fail to cross the phase I/II clinical trial threshold. One of the significant, but less commonly discussed, barriers in developing effective glioma therapy is the lack of a robust preclinical model. For the last 30 years, rodent orthotopic xenograft models have been extensively used in the preclinical setting. Although they provide a good basic model for understanding tumor biology, their value in successfully translating preclinical therapeutic triumph into clinical success is extremely poor. Companion dogs, which share the same environmental stress as their human counterparts, also spontaneously develop MGs. Dog gliomas that develop spontaneously in an immunocompetent host are very similar to human gliomas and potentially provide a stronger platform for validating the efficacy of therapeutic strategies proven successful in preclinical mouse models. Integrating this model can accelerate development of effective therapeutic options that will benefit both human subjects and pet dogs.

AB - With the median survival of 14.6 months following best available standard of care, malignant gliomas (MGs) remain one of the biggest therapeutic challenges of the modern time. Although the last several decades have witnessed tremendous advancement in our understanding of MG and evolution of many successful preclinical therapeutic strategies, even the most successful preclinical therapeutic strategies often fail to cross the phase I/II clinical trial threshold. One of the significant, but less commonly discussed, barriers in developing effective glioma therapy is the lack of a robust preclinical model. For the last 30 years, rodent orthotopic xenograft models have been extensively used in the preclinical setting. Although they provide a good basic model for understanding tumor biology, their value in successfully translating preclinical therapeutic triumph into clinical success is extremely poor. Companion dogs, which share the same environmental stress as their human counterparts, also spontaneously develop MGs. Dog gliomas that develop spontaneously in an immunocompetent host are very similar to human gliomas and potentially provide a stronger platform for validating the efficacy of therapeutic strategies proven successful in preclinical mouse models. Integrating this model can accelerate development of effective therapeutic options that will benefit both human subjects and pet dogs.

KW - Canine glioma

KW - Comparative oncology

KW - Glioblastoma

KW - Malignant glioma spontaneous glioma

UR - http://www.scopus.com/inward/record.url?scp=85019690374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019690374&partnerID=8YFLogxK

U2 - 10.1093/neuonc/now109

DO - 10.1093/neuonc/now109

M3 - Article

C2 - 27298310

AN - SCOPUS:85019690374

VL - 19

SP - 312

EP - 322

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 3

ER -